Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN-27M + IMM27M
- Development stage
- Unknown
- Lead developer
- ImmuneOnco
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYN-27M + IMM27M is a combination of two closely related or identical monoclonal antibodies, developed as next-generation, ADCC-enhanced antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). These antibodies are designed to act as immune checkpoint inhibitors, bolstering antitumor immune responses by inhibiting CTLA-4’s function and enhancing T cell activation. The combination has shown activity in solid tumors—such as advanced breast cancer—especially in patients progressing after endocrine therapy. SYN-27M and IMM27M are being developed by ImmuneOnco Biopharma and are licensed to Instil Bio for development outside Greater China. Clinical development includes combination studies with other immunotherapies, such as SYN-2510, with ongoing trials in dose escalation and multiple solid tumor indications[1][2][5][6][7][10].
- Brand names
- AXN-27M + IMM27M
- Other names
- AXN-27M/IMM27MSYN-27M/IMM27M
02
Targets
FCGR3B (Fc gamma receptor III)
Beyond the preview
Go deeper on SYN-27M + IMM27M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN-27M + IMM27M.